Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.


Long-term disability in Parkinson's disease (PD) is related to progression of the underlying disease and the emergence of complications of chronic levodopa therapy. There is a need for new medications that can slow the underlying progression of degeneration, improve PD symptoms in early disease without inducing dyskinesia, and improve motor fluctuations and… (More)


  • Presentations referencing similar topics